In this issue:
Pembrolizumab + chemotherapy in metastatic NSCLC
PD-1 blockade with cemiplimab in advanced cutaneous SCC
Tremelimumab + durvalumab in mesothelioma
Tasadenoturev (oncolytic adenovirus) in recurrent malignant glioma
Pembrolizumab for thymic carcinoma
Nivolumab ±ipilimumab in melanoma brain metastases
Nivolumab ±ipilimumab for metastatic sarcoma
Autologous dendritic cell vaccine in newly diagnosed glioblastoma
Pretreatment NLR and outcomes in immunotherapy-treated advanced cancer
What’s the most appropriate primary endpoint for immune checkpoint inhibitors?
Please login below to download this issue (PDF)